perrigo company plc, a top five global over-the-counter (otc) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. from its beginnings in 1887 as a packager of generic home remedies, perrigo, headquartered in ireland, has grown to become the world's largest manufacturer of otc products and supplier of infant formulas for the store brand market. the company is also a leading provider of branded otc products, generic extended topical prescription products and receives royalties from multiple sclerosis drug tysabri®. perrigo provides “quality affordable healthcare products®” across a wide variety of product categories and geographies primarily in north america, europe, and australia, as well as other key markets including israel and china. visit perrigo online at (http://www.perrigo.com).
Company profile
Ticker
PRGO
Exchange
Website
CEO
Murray Kessler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PERRIGO Co Ltd
SEC CIK
Corporate docs
Subsidiaries
Chefaro Ireland • Habsont Unlimited Company • Omega Teknika Designated Activity Company • Perrigo Corporation • Perrigo Finance Unlimited Company • Perrigo Holdings Unlimited Company • Perrigo International Finance • Perrigo Ireland • Perrigo Pharma International • Perrigo Science Eight Unlimited Company ...
PRGO stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
22 Mar 24
DEFA14A
Additional proxy soliciting materials
22 Mar 24
DEF 14A
Definitive proxy
22 Mar 24
PRE 14A
Preliminary proxy
12 Mar 24
8-K
Departure of Directors or Certain Officers
6 Mar 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results From Continuing Operations; Launches Investment & Efficiency Program
27 Feb 24
8-K
Entry into a Material Definitive Agreement
15 Dec 23
8-K
Perrigo Announces Early Results of Cash Tender Offer for Notes
29 Nov 23
Transcripts
PRGO
Earnings call transcript
2023 Q4
27 Feb 24
PRGO
Earnings call transcript
2023 Q3
7 Nov 23
PRGO
Earnings call transcript
2023 Q2
8 Aug 23
PRGO
Earnings call transcript
2023 Q1
9 May 23
PRGO
Earnings call transcript
2022 Q3
8 Nov 22
PRGO
Earnings call transcript
2022 Q2
9 Aug 22
PRGO
Earnings call transcript
2022 Q1
11 May 22
PRGO
Earnings call transcript
2021 Q4
1 Mar 22
PRGO
Earnings call transcript
2021 Q3
10 Nov 21
PRGO
Earnings call transcript
2021 Q2
11 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jul 23 | Apr 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Apr 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
92.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 359 |
Opened positions | 63 |
Closed positions | 40 |
Increased positions | 126 |
Reduced positions | 127 |
13F shares | Current |
---|---|
Total value | 3.97 tn |
Total shares | 124.63 mm |
Total puts | 245.60 k |
Total calls | 2.19 mm |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 14.90 mm | $476.15 bn |
BLK Blackrock | 12.91 mm | $412.38 bn |
Dimensional Fund Advisors | 6.49 mm | $207.46 bn |
Wolf Hill Capital Management | 6.42 mm | $204.98 bn |
STT State Street | 4.37 mm | $139.57 bn |
Cooke & Bieler | 3.51 mm | $112.12 bn |
Coho Partners | 3.20 mm | $102.31 bn |
DAVENPORT & Co | 3.17 mm | $101.05 bn |
London Co Of Virginia | 2.82 mm | $90.05 bn |
Deprince Race & Zollo | 2.69 mm | $86.03 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Alison Ives | RSU Ordinary Shares | Grant | Acquire A | No | No | 0 | 7,166 | 0.00 | 7,166 |
5 Apr 24 | Hanson Kyle | RSU Ordinary Shares | Grant | Acquire A | No | No | 0 | 12,420 | 0.00 | 12,420 |
5 Apr 24 | Eduardo Guarita Bezerra | RSU Ordinary Shares | Grant | Acquire A | No | No | 0 | 17,197 | 0.00 | 17,197 |
5 Apr 24 | Thomas Farrington | RSU Ordinary Shares | Grant | Acquire A | No | No | 0 | 6,640 | 0.00 | 6,640 |
5 Apr 24 | Robert Willis | RSU Ordinary Shares | Grant | Acquire A | No | No | 0 | 6,210 | 0.00 | 6,210 |
News
Canaccord Genuity Maintains Buy on Perrigo, Maintains $42 Price Target
12 Apr 24
Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
8 Apr 24
Piper Sandler Maintains Overweight on Perrigo, Raises Price Target to $39
8 Apr 24
CVS Health's Zero-Cost Coverage Paves Way For OTC Birth Control Access
5 Apr 24
'Supreme Court Unlikely To Limit Access To Abortion Pill' - Washington Post
26 Mar 24
Press releases
Opill and WNBA Team Up for Groundbreaking Partnership
9 Apr 24
Perrigo Commences Shipments of Opill® to Retailers Nationwide, Empowering Millions to Enter a New Era of Reproductive Health Access in the United States
4 Mar 24
Perrigo to Attend UBS Global Consumer and Retail Conference
29 Feb 24
Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results From Continuing Operations; Launches Investment & Efficiency Program
27 Feb 24
Perrigo Increases its Quarterly Dividend
26 Feb 24